The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
July 5th 2023
This cardiology case report from Brady Pregerson, MD, features a man in his late 80s presenting to urgent care with multiple episodes of near syncope in the past 3 days. Check out the ECG and determine the correct diagnosis!
6th Annual Advanced Practice Collaborative
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
Addressing Healthcare Inequities in Stroke Care: How Can We Play an Active Role in Improving Outcomes for All Patients?
Understanding Best Care Practices for Hemorrhagic Stroke – A Focus on the Role of DOAC Reversals
Announced by AGEPHA Pharma US on June 20, 2023, the US FDA approval of colchicine 0.5 mg tablets (Lodoco) for reducing cardiovascular event risk marks the first approval in agency history for an anti-inflammatory atheroprotective cardiovascular treatment.
This cardiology case report from Brady Pregerson, MD, features man in his late-60s presenting to urgent care with 3 days of upper respiratory infection symptoms and one episode of near syncope. Check out the ECG and see if you can determine the correct diagnosis!
On June 15, 2023, Bristol Myers Squibb announced the FDA approved an updated label for mavacamten (Camzyos) to reflect the agent's ability to reduce the need or eligibility for septal reduction therapy in patients with obstructive HCM based on VALOR-HCM.
New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.
Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.
An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.
An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.
Announced in a release by Daiichi Sankyo, Inc. and American Regent, Inc., the therapy is now the first and only intravenous iron replacement therapy indicated for adult patients with heart failure who have iron deficiency.
The analysis of adults with Type 2 diabetes found 33.4% showed signs of undetected CVD, as indicated by elevated levels of 2 cardiac biomarkers, compared to only 16.1% of those without diabetes.
Pooling data from half a dozen major population-based cohort studies, a Johns Hopkins-led team provides new insight into the risk of cognitive decline following myocardial infarction among US adults.
Scott Solomon, MD, of Brigham and Women's Hospital, discusses how baseline patient characteristics inform what cardiologists might learn from the FINEARTS-HF trial, which he presented at Heart Failure 2023.
Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.